ArticleIn vitro cellular & developmental biology. Animal2026
Decorin inhibits the migration and invasion of the LPS + high glucose-induced primary trophoblast cell through ADAMTS12.
Article in In vitro cellular & developmental biology. Animal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Decorin was identified as the most relevant biomarker in type 2 diabetes or obesity-related diseases, but its function in gestational obesity or gestational diabetes mellitus (GDM) remains unknown. RT-qPCR or western blot were employed to validate the expression of Decorin and ADAMTS12 in the umbilical cord blood or placental tissues of the aforementioned groups. Subsequently, an LPS + high glucose-induced primary trophoblast cell model was established to verify the expression of DCN and ADAMTS12 in trophoblasts. Based on this model, silencing (si) of Decorin, or Decorin recombinant protein (DCN-r) combined with si-ADAMTS12 intervention, was performed to investigate its effects on trophoblast cell proliferation, migration, invasion, and other characteristics. Compared to the normal pregnancy group, the levels of DCN and ADAMTS12 showed an increasing trend in the gestational obesity group and the GDM group. Notably, DCN and ADAMTS12 were markedly higher in the GDM with obesity group compared to either the gestational obesity or GDM-alone groups. LPS + high glucose inhibited the migration and invasion of primary trophoblast cells while promoting increased levels of DCN and ADAMTS12. Under LPS + high-glucose intervention, DCN-r further suppressed trophoblast cell migration and invasion while enhancing ADAMTS12 expression, whereas si-DCN reversed these effects. Additionally, si-ADAMTS12 attenuated the LPS + high glucose-induced decline in trophoblast cell migration and invasion and blocked the promoting effects of DCN recombinant protein. Silencing ADAMTS12 can inhibit the promotive effect of DCN on the migration and invasion capabilities of LPS + high glucose-induced primary trophoblast cells. Clinical trial number: not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.